-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| U. Xinhua News Agency, Washington, February 27 (Reporter Tan Jingjing) The US Food and Drug Administration approved an emergency use authorization application for the new crown vaccine developed by Johnson Pharmaceuticals, a subsidiary of Johnson & Johnson, on the 27th. The US Drug Administration said in a statement that this emergency use authorization allows the new crown vaccine to be distributed throughout the United States. Janet Woodcock, acting director of the US Drug Administration, pointed out in a statement that the epidemic has claimed the lives of more than 500,000 Americans. She said that after an open and transparent scientific evaluation process, the US Drug Administration has approved three new coronavirus vaccines. According to the official website of the US Drug Administration, emergency use authorization is not equivalent to formal approval. Johnson & Johnson Vaccine is a recombinant adenovirus vector vaccine and the third vaccine approved for emergency use in the United States. According to the website of the U. aspx?id=3570" target="_blank" style="color:#ba1413">Focus on the new crown pneumonia epidemic
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
Welcome to ECHEMI 
|
